[go: up one dir, main page]

MX2009010757A - Metodos de uso de compuestos de inhibidor gamma para atenuacion del dolor. - Google Patents

Metodos de uso de compuestos de inhibidor gamma para atenuacion del dolor.

Info

Publication number
MX2009010757A
MX2009010757A MX2009010757A MX2009010757A MX2009010757A MX 2009010757 A MX2009010757 A MX 2009010757A MX 2009010757 A MX2009010757 A MX 2009010757A MX 2009010757 A MX2009010757 A MX 2009010757A MX 2009010757 A MX2009010757 A MX 2009010757A
Authority
MX
Mexico
Prior art keywords
pain
methods
attenuation
inhibitor compounds
gamma inhibitor
Prior art date
Application number
MX2009010757A
Other languages
English (en)
Inventor
Stephen D Harrison
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Publication of MX2009010757A publication Critical patent/MX2009010757A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La descripción de la presente solicitud se refiere a péptidos inhibidores de ?PKC modificados, a métodos para generar dichos péptidos, y a método para utilizar péptidos inhibidores de ?PKC para tratamiento del dolor.
MX2009010757A 2007-04-06 2008-04-07 Metodos de uso de compuestos de inhibidor gamma para atenuacion del dolor. MX2009010757A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91058807P 2007-04-06 2007-04-06
PCT/US2008/059591 WO2008124698A2 (en) 2007-04-06 2008-04-07 Methods of use of gamma inhibitor compounds for the attenuation of pain

Publications (1)

Publication Number Publication Date
MX2009010757A true MX2009010757A (es) 2010-02-24

Family

ID=39831558

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010757A MX2009010757A (es) 2007-04-06 2008-04-07 Metodos de uso de compuestos de inhibidor gamma para atenuacion del dolor.

Country Status (8)

Country Link
US (1) US20090062178A1 (es)
EP (1) EP2144615A4 (es)
JP (1) JP2010523598A (es)
CN (1) CN101969960A (es)
AU (1) AU2008237138B2 (es)
CA (1) CA2693256A1 (es)
MX (1) MX2009010757A (es)
WO (1) WO2008124698A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017583B2 (en) * 2007-01-19 2011-09-13 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain
JP5801197B2 (ja) * 2008-09-03 2015-10-28 ノノ インコーポレイテッド 痛みの治療に関する薬剤及び方法
US11208446B2 (en) 2016-11-01 2021-12-28 Memorial Sloan Kettering Cancer Cenier Agents and methods for treating CBP-dependent cancers
IT201800009384A1 (it) * 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
AU784727B2 (en) * 2000-02-08 2006-06-01 Amgen, Inc. IL-17 like molecules and uses thereof
CA2481512C (en) * 2002-04-22 2013-06-18 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c.gamma. for pain management
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US8017583B2 (en) * 2007-01-19 2011-09-13 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain

Also Published As

Publication number Publication date
EP2144615A2 (en) 2010-01-20
CN101969960A (zh) 2011-02-09
EP2144615A4 (en) 2011-02-16
AU2008237138A1 (en) 2008-10-16
WO2008124698A2 (en) 2008-10-16
US20090062178A1 (en) 2009-03-05
AU2008237138B2 (en) 2013-11-21
JP2010523598A (ja) 2010-07-15
CA2693256A1 (en) 2008-10-16
WO2008124698A3 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
IN2012DN03883A (es)
TN2009000224A1 (en) Inhibitors of akt activity
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MX2011007930A (es) Conjugados de insulina cristalina.
WO2010071846A3 (en) Compounds for treating neuropsychiatric conditions
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
MX2015011097A (es) Inhibidores de histona desmetilasas.
TW200626068A (en) Active compounds for seed treatment
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
UA89226C2 (en) Imidazole compounds
MX2012004780A (es) Inhibidores de akt.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MY155340A (en) Use of cathepsin c
MX2009010757A (es) Metodos de uso de compuestos de inhibidor gamma para atenuacion del dolor.
WO2008089494A3 (en) Methods of use of epsilon inhibitor compounds for the attenuation of pain
WO2010148177A3 (en) Compounds, compositions, methods of synthesis, and methods of treatment
TN2011000214A1 (en) Combination of hsp90 and herceptin inhibitors
NZ586723A (en) Use of Biota orientalis for treating osteoarthritis
WO2009105507A3 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain

Legal Events

Date Code Title Description
FA Abandonment or withdrawal